✦ LIBER ✦

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

✍ Scribed by Scott D Solomon; Michael Zile; Burkert Pieske; Adriaan Voors; Amil Shah; Elisabeth Kraigher-Krainer; Victor Shi; Toni Bransford; Madoka Takeuchi; Jianjian Gong; Martin Lefkowitz; Milton Packer; John JV McMurray

Book ID: 118553434
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 353 KB
Volume: 380
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(12)61227-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Angiotensin Receptor Neprilysin Inhi

The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase II Randomised-Controlled Trial

✍ Scott D. Solomon; Michael Zile; Burkert Pieske; Adriaan A. Voors; Amil Shah; Eli 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 69 KB

THE EFFICACY OF THE ANGIOTENSIN RECEPTOR

THE EFFICACY OF THE ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR, LCZ696, IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION IS INDEPENDENT OF BLOOD PRESSURE LOWERING

✍ Jhund, Pardeep; Claggett, Brian; Packer, Milton; Zile, Michael; Voors, Adriaan; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 190 KB

Independence of the blood pressure lower

Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial

✍ Jhund, Pardeep S.; Claggett, Brian; Packer, Milton; Zile, Michael R; Voors, Adri 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 603 KB

Blood-pressure reduction with LCZ696, a

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

✍ Luis Miguel Ruilope; Andrej Dukat; Michael Böhm; Yves Lacourcière; Jianjian Gong 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 377 KB

Clazosentan, an endothelin receptor anta

Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2)

✍ R Loch Macdonald; Randall T Higashida; Emanuela Keller; Stephan A Mayer; Andy Mo 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 284 KB

Safety and Efficacy of the Specific Endo

Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial

✍ Nicholas D. James; Armelle Caty; Michael Borre; Bernard A. Zonnenberg; Philippe 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 1000 KB